MajorFirst-generation antipsychotic, aliphatic-side-chain phenothiazine×Class III antiarrhythmic, selective IKr blocker
Updated · Methodology
Mechanism
Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). Chlorpromazine is a phenothiazine neuroleptic. Phenothiazine neuroleptics can potentiate QT prolongation, which raises the risk of serious, potentially fatal ventricular arrhythmias of the torsade de pointes type (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the Spanish chlorpromazine SmPC, the risk of arrhythmia increases when chlorpromazine is used with QT-prolonging drugs, including some antiarrhythmics (AEMPS). The documents describe no pharmacokinetic interaction for this pair (chlorpromazine SmPC, AEMPS; dofetilide FDA label).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death. In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment (dofetilide label, US Food and Drug Administration, FDA). With chlorpromazine, QT prolongation on the ECG is a common adverse reaction. Ventricular arrhythmia, ventricular fibrillation and tachycardia, torsade de pointes, cardiac arrest and sudden death occur with unknown frequency (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
Avoid the combination. The US dofetilide label does not recommend dofetilide with other drugs that prolong the QT interval and names phenothiazines among them (dofetilide label, US Food and Drug Administration, FDA). Chlorpromazine is a phenothiazine (chlorpromazine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish chlorpromazine SmPC also does not recommend chlorpromazine with other QT-prolonging drugs (AEMPS), and dofetilide prolongs QT according to its own label (FDA). No document contraindicates the combination, and dofetilide is not in the Spanish medicines register CIMA. According to the Spanish chlorpromazine SmPC, before starting chlorpromazine, rule out a heart rate below 55 beats per minute, low potassium and congenital QT prolongation where clinically possible. Also rule out ongoing treatment with drugs that can cause marked bradycardia, low potassium, slowed intracardiac conduction or QT prolongation. Except in emergencies, the initial assessment should include an electrocardiogram (ECG) (AEMPS). If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug (FDA). No document states how long to wait after stopping chlorpromazine before starting dofetilide. The half-life of chlorpromazine varies and is close to 30 hours (AEMPS). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous ECG monitoring and perform cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Keep potassium in the normal range before and during treatment (FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Clorpromazina (nº registro 42934), sección 4.4 (2023)– AEMPS, CIMA, nº registro 42934 (Largactil 100 mg comprimidos recubiertos con película, Neuraxpharm Spain), revisión 07/2023, secciones 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: TIKOSYN (dofetilide) capsules prescribing information (2026)– FDA, DailyMed setid 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (Pfizer), revisión 04/2026 (versión 30), Boxed Warning, Contraindications, Warnings (Ventricular Arrhythmia, Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents), Precautions (Drug-Drug Interactions), Dosage and Administration